BioNTech stock ends the day higher after the close

At the close on September 21, 2026, BioNTech stock finished higher on Nasdaq, with BioNTech shares at USD 97.71 and up 2.00 percent in late trading coverage after a Reuters note on biotech read-through. Berenberg also lifted its target to USD 140.

BioNTech stock closed at USD 97.71 on Nasdaq on September 21, 2026, up 2.00 percent from the prior close. The move came alongside broader biotech strength, while the U.S.-listed shares of BioNTech SE (ISIN US09075V1026, Nasdaq: BNTX) traded above the prior session's USD 96.06 close.

Closing wrap on September 21, 2026

BioNTech SE (ISIN US09075V1026, Nasdaq: BNTX) finished the U.S. session at USD 97.71, and the day range in the market coverage ran from USD 96.06 to USD 97.71. Reuters reported that the stock moved with a wider biotech read-through after Moderna-related cancer-immunotherapy headlines, and it also noted BioNTech's shares were up 1.2 percent in Monday trading coverage. The price finished 1.65 dollars above the reference close.

As Reuters reported, global stocks rose on Monday as tech sentiment improved, and that market backdrop helped frame the session for biotech names. BioNTech also had a fresh analyst note on the day: ad hoc news said Berenberg raised its BioNTech target to USD 140 and kept a Buy rating on September 21, 2026.

After the close on September 21, 2026

After the close, BioNTech shares were still moving in after-hours coverage, with Yahoo Finance showing the stock at USD 97.71 and up 2 percent, and Pluang showing USD 97.32 and up 1.31 percent later in the evening. Reuters-linked trading coverage also said BioNTech announced it scrapped a clinical trial for its own mRNA cancer vaccine, a development that remained part of the session backdrop for the next trading day.